{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:06:17Z","timestamp":1791396377011,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013595","name":"AMAG Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s12325-021-01770-2","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T10:40:26Z","timestamp":1622803226000},"page":"3531-3549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-9076","authenticated-orcid":false,"given":"John A.","family":"Glaspy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,30]]},"reference":[{"issue":"11","key":"1770_CR1","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2169\/naika.71.1566","volume":"71","author":"M Okada","year":"1982","unstructured":"Okada M, Imamura K, Fuchigami T, et al. 2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide. Nihon Naika Gakkai Zasshi. 1982;71(11):1566\u201372.","journal-title":"Nihon Naika Gakkai Zasshi"},{"issue":"2","key":"1770_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01496662","volume":"61","author":"M Okada","year":"1983","unstructured":"Okada M, Imamura K, Iida M, Fuchigami T, Omae T. Hypophosphatemia induced by intravenous administration of saccharated iron oxide. Klin Wochenschr. 1983;61(2):99\u2013102.","journal-title":"Klin Wochenschr"},{"issue":"1","key":"1770_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S8756-3282(97)00084-7","volume":"21","author":"K Sato","year":"1997","unstructured":"Sato K, Nohtomi K, Demura H, et al. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin\u00a0D production in renal tubules. Bone. 1997;21(1):57\u201364.","journal-title":"Bone"},{"issue":"4","key":"1770_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1507\/endocrj.45.431","volume":"45","author":"K Sato","year":"1998","unstructured":"Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J. 1998;45(4):431\u20139.","journal-title":"Endocr J"},{"issue":"Pt 2","key":"1770_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46(Pt 2):167\u20139.","journal-title":"Ann Clin Biochem"},{"issue":"7","key":"1770_CR6","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94(7):2332\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1770_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","volume":"26","author":"H Zoller","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017;26(4):266\u201375.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"Suppl 1","key":"1770_CR8","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1182\/blood-2018-99-114386","volume":"132","author":"IE Emrich","year":"2018","unstructured":"Emrich IE, Lizzi F, Seiler-Mu\u00dfler S, et al. Hypophosphatemia after high dosage iron substitution with ferric carboxymaltose (FCM) and iron isomaltoside (IM)\u2014the randomised controlled Home Afers 1 trial. Blood. 2018;132(Suppl 1):3627.","journal-title":"Blood"},{"key":"1770_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/TCRM.S243462","volume":"16","author":"JA Glaspy","year":"2020","unstructured":"Glaspy JA, Lim-Watson MZ, Libre MA, et al. Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review. Ther Clin Risk Manag. 2020;16:245\u201359.","journal-title":"Ther Clin Risk Manag"},{"key":"1770_CR10","doi-asserted-by":"crossref","unstructured":"Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3(23):e124486.","DOI":"10.1172\/jci.insight.124486"},{"key":"1770_CR11","doi-asserted-by":"publisher","first-page":"172104","DOI":"10.1155\/2012\/172104","volume":"2012","author":"CF Barish","year":"2012","unstructured":"Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials. Anemia. 2012;2012:172104.","journal-title":"Anemia"},{"issue":"2","key":"1770_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5414\/CNP71125","volume":"71","author":"AC Grimmelt","year":"2009","unstructured":"Grimmelt AC, Cohen CD, Fehr T, Serra AL, Wuethrich RP. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol. 2009;71(2):125\u20139.","journal-title":"Clin Nephrol"},{"issue":"5","key":"1770_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","volume":"26","author":"WY Qunibi","year":"2011","unstructured":"Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26(5):1599\u2013607.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"1770_CR14","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","volume":"49","author":"DB Van Wyck","year":"2009","unstructured":"Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719\u201328.","journal-title":"Transfusion"},{"key":"1770_CR15","doi-asserted-by":"crossref","unstructured":"Anand G, Schmid C. Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep. 2017;2017:bcr2016219160.","DOI":"10.1136\/bcr-2016-219160"},{"issue":"3","key":"1770_CR16","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jbmr.3319","volume":"33","author":"J Bartko","year":"2018","unstructured":"Bartko J, Roschger P, Zandieh S, Brehm A, Zwerina J, Klaushofer K. Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J Bone Miner Res. 2018;33(3):534\u20139.","journal-title":"J Bone Miner Res"},{"issue":"1\u20132","key":"1770_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1177\/2042018816678363","volume":"8","author":"RH Bishay","year":"2017","unstructured":"Bishay RH, Ganda K, Seibel MJ. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab. 2017;8(1\u20132):14\u20139.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"5","key":"1770_CR18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/jgh3.12150","volume":"3","author":"W Fang","year":"2019","unstructured":"Fang W, McMahon LP, Bloom S, Garg M. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 2019;3(5):438\u201340.","journal-title":"JGH Open"},{"key":"1770_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222851","author":"K Klein","year":"2018","unstructured":"Klein K, Asaad S, Econs M, Rubin JE. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep. 2018. https:\/\/doi.org\/10.1136\/bcr-2017-222851.","journal-title":"BMJ Case Rep"},{"issue":"3","key":"1770_CR20","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/jbmr.3369","volume":"33","author":"T Urbina","year":"2018","unstructured":"Urbina T, Belkhir R, Rossi G, et al. Iron supplementation-induced phosphaturic osteomalacia: FGF23 is the culprit. J Bone Miner Res. 2018;33(3):540\u20132.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1770_CR21","first-page":"594","volume":"71","author":"G Vasquez-Rios","year":"2018","unstructured":"Vasquez-Rios G, Marin E, Martin K, Merando A. Harder to breathe: an unusual case of severe hyperphosphaturic hypophosphatemia and normal FGF-23 levels in a young female patient [abstract 314]. Am J Kidney Dis. 2018;71(4):594.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"1770_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ajh.25060","volume":"93","author":"NF Adkinson","year":"2018","unstructured":"Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93(5):683\u201390.","journal-title":"Am J Hematol"},{"issue":"5","key":"1770_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2019.22450","volume":"323","author":"M Wolf","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323(5):432\u201343.","journal-title":"JAMA"},{"key":"1770_CR24","doi-asserted-by":"publisher","first-page":"468675","DOI":"10.1155\/2015\/468675","volume":"2015","author":"S Hardy","year":"2015","unstructured":"Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675.","journal-title":"Int J Rheumatol"},{"issue":"1","key":"1770_CR25","first-page":"49","volume":"72","author":"A Blazevic","year":"2014","unstructured":"Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72(1):49\u201353.","journal-title":"Neth J Med"},{"issue":"4","key":"1770_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/apt.15386","volume":"50","author":"TE Detlie","year":"2019","unstructured":"Detlie TE, Lindstrom JC, Jahnsen ME, et al. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther. 2019;50(4):397\u2013406.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"1770_CR27","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28(8):1793\u2013803.","journal-title":"J Bone Miner Res"},{"key":"1770_CR28","first-page":"497","volume":"3","author":"S Fukumoto","year":"2014","unstructured":"Fukumoto S. Phosphate metabolism and vitamin\u00a0D. Bonekey Rep. 2014;3:497.","journal-title":"Bonekey Rep"},{"issue":"1","key":"1770_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ki.2012.327","volume":"83","author":"J Arnlov","year":"2013","unstructured":"Arnlov J, Carlsson AC, Sundstrom J, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int. 2013;83(1):160\u20136.","journal-title":"Kidney Int"},{"issue":"4","key":"1770_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/ki.2013.150","volume":"84","author":"M Christov","year":"2013","unstructured":"Christov M, Waikar SS, Pereira RC, et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int. 2013;84(4):776\u201385.","journal-title":"Kidney Int"},{"issue":"11","key":"1770_CR31","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408.","journal-title":"J Clin Invest"},{"issue":"6","key":"1770_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584\u201392.","journal-title":"N Engl J Med"},{"issue":"19","key":"1770_CR33","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545\u201352.","journal-title":"Circulation"},{"issue":"12","key":"1770_CR34","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370\u20138.","journal-title":"Kidney Int"},{"issue":"23","key":"1770_CR35","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432\u20139.","journal-title":"JAMA"},{"issue":"3","key":"1770_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","volume":"60","author":"JH Ix","year":"2012","unstructured":"Ix JH, Katz R, Kestenbaum BR, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012;60(3):200\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1770_CR37","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152(10):640\u20138.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1770_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1681\/ASN.2012070713","volume":"24","author":"JJ Scialla","year":"2013","unstructured":"Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol. 2013;24(1):125\u201335.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1770_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrneph.2014.49","volume":"10","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268\u201378.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"1770_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, et al. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014;25(2):349\u201360.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"1770_CR41","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2215\/CJN.04430415","volume":"10","author":"M Wolf","year":"2015","unstructured":"Wolf M. Mineral (mal)adaptation to kidney disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol. 2015;10(10):1875\u201385.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"1770_CR42","first-page":"1628","volume":"33","author":"LL Huang","year":"2018","unstructured":"Huang LL, Lee D, Troster SM, et al. A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy. Nephrol Dial Transplant. 2018;33(9):1628\u201335.","journal-title":"Nephrol Dial Transplant"},{"key":"1770_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/PROM.S169653","volume":"9","author":"WE Strauss","year":"2018","unstructured":"Strauss WE, Auerbach M. Health-related quality of life in patients with iron deficiency anemia: impact of treatment with intravenous iron. Patient Relat Outcome Meas. 2018;9:285\u201398.","journal-title":"Patient Relat Outcome Meas"},{"issue":"10","key":"1770_CR44","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra041809","volume":"352","author":"G Weiss","year":"2005","unstructured":"Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011\u201323.","journal-title":"N Engl J Med"},{"key":"1770_CR45","doi-asserted-by":"publisher","first-page":"116692","DOI":"10.1016\/j.jns.2020.116692","volume":"411","author":"K Suzuki","year":"2020","unstructured":"Suzuki K, Suzuki S, Ishii Y, et al. Plasma prostaglandin D2 synthase levels in sleep and neurological diseases. J Neurol Sci. 2020;411:116692.","journal-title":"J Neurol Sci"},{"issue":"6","key":"1770_CR46","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1053\/j.gastro.2016.09.050","volume":"152","author":"B Schaefer","year":"2017","unstructured":"Schaefer B, Glodny B, Zoller H. Blood and bone loser. Gastroenterology. 2017;152(6):e5\u20136.","journal-title":"Gastroenterology"},{"issue":"02","key":"1770_CR47","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4172\/2165-7920.1000931","volume":"07","author":"M Reyes","year":"2017","unstructured":"Reyes M, Diamond T. Hypophosphataemic rickets due to parenteral ferrous carboxymaltose in a young man with crohn disease and iron deficiency: a case report and review of literature. J Clin Case Rep. 2017;07(02):931.","journal-title":"J Clin Case Rep"},{"issue":"5","key":"1770_CR48","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.endinu.2018.10.006","volume":"66","author":"S Gomez Rodriguez","year":"2019","unstructured":"Gomez Rodriguez S, Castro Ramos JC, Abreu Padin C, G\u00f3mez Peralta F. Intravenous iron induced severe hypophophatemia in a gastric bypass patient. Endocrinol Diabetes Nutr. 2019;66(5):340\u20132.","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"1499","key":"1770_CR49","first-page":"72","volume":"132","author":"YJ Chen","year":"2019","unstructured":"Chen YJ, Lim C, McCormick J. Resistant iron-induced hypophosphatemia following colorectal surgery. N Z Med J. 2019;132(1499):72\u20135.","journal-title":"N Z Med J"},{"issue":"2\u20133","key":"1770_CR50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ando.2020.04.008","volume":"81","author":"S Roman-Gimeno","year":"2020","unstructured":"Roman-Gimeno S, Ortez-Toro JJ, Peteiro-Miranda CM, Sanz-Martin B, Urdaniz-Borque R. Case report: a rare cause of severe hypophosphatemia. Ann Endocrinol (Paris). 2020;81(2\u20133):125\u20136.","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"1770_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/20009666.2020.1746521","volume":"10","author":"A Sullivan","year":"2020","unstructured":"Sullivan A, Lanham T, Rubin A. A rare case of parental iron-induced persistent hypophosphatemia. J Commun Hosp Intern Med Perspect. 2020;10(2):166\u20137.","journal-title":"J Commun Hosp Intern Med Perspect"},{"key":"1770_CR52","doi-asserted-by":"publisher","first-page":"100712","DOI":"10.1016\/j.bonr.2020.100712","volume":"13","author":"EL Callejas-Moraga","year":"2020","unstructured":"Callejas-Moraga EL, Casado E, Gomez-Nu\u00f1ez M, Caresia-Aroztegui AP. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome. Bone Rep. 2020;13:100712.","journal-title":"Bone Rep"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01770-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01770-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:19:37Z","timestamp":1626221977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01770-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,30]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01770-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,30]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}